Teva Pharmaceutical Industries (NYSE:TEVA) Lowered to “Sell” at ValuEngine

Teva Pharmaceutical Industries (NYSE:TEVA) was downgraded by stock analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued to investors on Thursday, ValuEngine reports.

Several other brokerages have also issued reports on TEVA. Morgan Stanley lowered shares of Teva Pharmaceutical Industries from an “equal weight” rating to an “underweight” rating and cut their target price for the company from $16.00 to $6.00 in a research report on Monday, July 15th. Oppenheimer set a $12.00 target price on shares of Teva Pharmaceutical Industries and gave the company a “buy” rating in a research report on Wednesday, June 12th. Sanford C. Bernstein cut their target price on shares of Teva Pharmaceutical Industries from $17.00 to $11.00 and set a “market perform” rating for the company in a research report on Tuesday, June 18th. They noted that the move was a valuation call. Wells Fargo & Co set a $17.00 target price on shares of Teva Pharmaceutical Industries and gave the company a “hold” rating in a research report on Tuesday, May 28th. Finally, Barclays assumed coverage on shares of Teva Pharmaceutical Industries in a research report on Tuesday, June 11th. They set an “underweight” rating and a $8.00 target price for the company. Six research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $15.13.

Shares of TEVA traded up $0.03 during mid-day trading on Thursday, hitting $7.86. 10,377,281 shares of the company traded hands, compared to its average volume of 18,220,274. The company has a debt-to-equity ratio of 1.66, a quick ratio of 0.62 and a current ratio of 0.96. The business has a 50-day moving average price of $8.52. Teva Pharmaceutical Industries has a 1 year low of $7.46 and a 1 year high of $25.96. The company has a market cap of $8.06 billion, a PE ratio of 2.81, a price-to-earnings-growth ratio of 0.83 and a beta of 1.64.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Thursday, May 2nd. The company reported $0.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.55 by $0.02. The company had revenue of $4.30 billion during the quarter, compared to analyst estimates of $4.38 billion. Teva Pharmaceutical Industries had a negative net margin of 18.66% and a positive return on equity of 16.84%. The firm’s quarterly revenue was down 15.2% compared to the same quarter last year. During the same period in the previous year, the business posted $0.94 earnings per share. Equities analysts expect that Teva Pharmaceutical Industries will post 2.26 earnings per share for the current fiscal year.

In other news, Director Sol J. Barer purchased 111,000 shares of the company’s stock in a transaction on Monday, June 3rd. The stock was acquired at an average cost of $8.98 per share, for a total transaction of $996,780.00. Following the completion of the transaction, the director now directly owns 115,942 shares in the company, valued at approximately $1,041,159.16. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Notaristefani Carlo De sold 16,070 shares of the company’s stock in a transaction that occurred on Monday, May 20th. The stock was sold at an average price of $11.42, for a total transaction of $183,519.40. Following the completion of the transaction, the vice president now owns 49,659 shares of the company’s stock, valued at $567,105.78. The disclosure for this sale can be found here. Corporate insiders own 0.49% of the company’s stock.

Large investors have recently modified their holdings of the stock. Kavar Capital Partners LLC bought a new position in shares of Teva Pharmaceutical Industries during the second quarter worth $35,000. G&S Capital LLC boosted its position in shares of Teva Pharmaceutical Industries by 99.4% during the second quarter. G&S Capital LLC now owns 4,012 shares of the company’s stock worth $37,000 after acquiring an additional 2,000 shares during the last quarter. Lindbrook Capital LLC boosted its position in shares of Teva Pharmaceutical Industries by 61.2% during the first quarter. Lindbrook Capital LLC now owns 2,489 shares of the company’s stock worth $39,000 after acquiring an additional 945 shares during the last quarter. NEXT Financial Group Inc boosted its position in shares of Teva Pharmaceutical Industries by 384.8% during the second quarter. NEXT Financial Group Inc now owns 4,276 shares of the company’s stock worth $39,000 after acquiring an additional 3,394 shares during the last quarter. Finally, Cullen Frost Bankers Inc. bought a new position in shares of Teva Pharmaceutical Industries during the first quarter worth $40,000. Hedge funds and other institutional investors own 65.48% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Featured Story: What is the balance sheet?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.